ANALISIS EFEKTIVITAS BIAYA TERAPI HEPARIN DAN FONDAPARINUX PADA PENDERITA SINDROMA KORONER AKUT TANPA ELEVASI SEGMEN ST
| Main Authors: | , MARTOHAP PAROTUA LUMBAN RAJA, , Ika Puspitasari, Ph.D., Apt. |
|---|---|
| Format: | Thesis NonPeerReviewed |
| Terbitan: |
[Yogyakarta] : Universitas Gadjah Mada
, 2013
|
| Subjects: | |
| Online Access: |
https://repository.ugm.ac.id/120772/ http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=60810 |
Daftar Isi:
- Acute coronary syndrome (ACS) is a clinical manifestation of coronary heart disease which often causes death due to occlusion in coronary artery which develops acutely. The combined use of antithrombotic agents, antiplatelet agents in acute coronary syndrome syndrome without ST-segment elevation (ACS WSTE) reduces cardiovascular event but increasing the side effects of bleeding. The objective of the research is to compare the effectiveness, safety and evaluate the cost effectiveness of heparin versus fondaparinux in 62 patients with ACS WSTE at Dr. Sardjito Central General Hospital from perpective of provider (hospital). Observation on heparin and fondarinux effectiveness outcome (death, myocardial infarction, and stroke) and safety (major and minor bleeding) during hospitalization and up to 30 days. The result on effectiveness observation showed the number of ACS patients who died until the 30th day in heparin group was two patients (6,4%) and in fondaparinux group was one patient (3,2%). The number of patients ended up with a stroke in heparin group was one patient (3,2%), while in fondaparinux group no patients experienced any stroke p= 1. The result on the safety observation signified that the number of ACS patients experiencing major bleeding up to 30 days was two patients (6,4%), while no patients suffered from bleeding in the fondaparinux group p= 0,492. The number of ACS WSTE patients who had minor bleeding in heparin group was 10 patients (32,2%), while in fondaparinux group was two patients (6,4%) p=0,010. The ACS WSTE�s treatment cost for 30 days for fondaparinux group was lower (IDR 8,551,057.-) than heparin group which was IDR 10,171,157.- p= 0,013. The average cost effectiveness ratio of patients who received the fondaparinux theraphy up to 30 days was IDR 8,833,736.-, while for the patients given the heparin theraphy was IDR 10,878,243.-. The conclusion of the research is that fondaparinux is more cost-effective than heparin.